• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Forte Biosciences Inc.

    9/30/25 4:05:45 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FBRX alert in real time by email
    S-8 1 d83263ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on September 30, 2025

    Registration No. 333-    

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

     

    FORTE BIOSCIENCES, INC.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware   26-1243872

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    3060 Pegasus Park Drive, Building 6

    Dallas, Texas 75247

    (Address of Principal Executive Offices, including zip code)

    2020 Inducement Equity Incentive Plan

    (Full title of the plan)

    Paul A. Wagner, Ph.D.

    Chief Executive Officer

    Forte Biosciences, Inc.

    3060 Pegasus Park Drive, Building 6

    Dallas, Texas 75247

    (310) 618-6994

    (Name, address and telephone number, including area code, of agent for service)

    Copies to:

    Dan Koeppen

    Ben Capps

    Wilson Sonsini Goodrich & Rosati, P.C.

    12235 El Camino Real

    San Diego, California 92130

    (858) 350-2300

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer ☐   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     
     


    EXPLANATORY NOTE

    Forte Biosciences, Inc. (the “Registrant”) is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register 1,000,000 additional shares of common stock of the Registrant, par value $0.001 per share (“Common Stock”) under the Registrant’s 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”).

    These additional shares of common stock are securities of the same class as other securities for which previous Registration Statements on Form S-8 were filed by the Registrant with the Securities and Exchange Commission (the “SEC”) on April 12, 2024 (File No. 333-278647) and August 11, 2020 (File No. 333-278647) (the “Previous Registration Statements”). In accordance with General Instruction E of Form S-8, the contents of the Previous Registration Statements, including periodic reports filed after the Previous Registration Statements to maintain current information about the Registrant, are incorporated by reference into this Registration Statement.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”) and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plan covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

    PART II

    INFORMATION REQUIRED IN REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the Commission:

     

    (1)    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 28, 2025.
    (2)    The information specifically incorporated by reference into our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 from the Registrant’s Definitive Proxy Statement on Schedule 14A filed on April 30, 2025.
    (3)    The Registrant’s Quarterly Report on Form 10-Q for its fiscal quarter ended March 31, 2025 and its Quarterly Report on Form 10-Q for its fiscal quarter ended June 30, 2025, filed with the Commission on May 15, 2025 and August 14, 2025, respectively.
    (4)    All other reports filed with the Commission pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since the end of the fiscal year covered by the Registrant’s Annual Report referred to in (1) above.
    (5)    The description of the Registrant’s common stock contained in the Company’s Annual Report on Form 10-K filed with the Commission on February 27, 2020, pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been


    furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Under no circumstances will any information furnished under current items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

    Item 5. Interests of Named Experts and Counsel.

    The validity of the issuance of the shares of the Registrant’s Common Stock offered hereby has been passed upon by Wilson Sonsini Goodrich & Rosati, Professional Corporation (“WSGR”). Certain members of, and investment partnerships comprised of members of, and persons associated with, WSGR, directly or indirectly, own less than 0.3% of the outstanding shares of the Registrant’s Common Stock.

    Item 6. Indemnification of Directors and Officers.

    The Registrant’s amended and restated certificate of incorporation provides that to the fullest extent permitted by applicable law, the Registrant is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Registrant (and any other persons to which applicable law permits the Registrant to provide indemnification) through bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise in excess of the indemnification and advancement otherwise permitted by such applicable law. If applicable law is amended after approval by the stockholders of the Registrant’s amended and restated certificate of incorporation to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director to the Registrant shall be eliminated or limited to the fullest extent permitted by applicable law as so amended.

    The Registrant’s amended and restated bylaws provide that the Registrant shall indemnify its directors and officers to the extent not prohibited by the Delaware General Corporate Law (“DGCL”) or any other applicable law; provided, however, that the Registrant may modify the extent of such indemnification by individual contracts with its directors and officers; and, provided, further, that the Registrant shall not be required to indemnify any director or officer in connection with any proceeding (or part thereof) initiated by such person unless (i) such indemnification is expressly required to be made by law, (ii) the proceeding was authorized by the Registrant’s Board of Directors, (iii) such indemnification is provided by the Registrant, in its sole discretion, pursuant to the powers vested in the Registrant under the DGCL or any other applicable law or (iv) such indemnification is otherwise required to be made the amended and restated bylaws. The Registrant’s amended and restated bylaws also permit it to advance expenses to any director or officer who was or is a party or is threatened to be made a party to any action by reason of such status.

    The rights conferred in the amended and restated certificate of incorporation and amended and restated bylaws are not exclusive, and the Registrant is authorized to enter into indemnification agreements with its directors, officers, employees, and agents and to obtain insurance to indemnify such persons.

    The Registrant has entered into indemnification agreements with its directors and executive officers that provide the maximum indemnity allowed to directors and executive officers by Section 145 of the DGCL and also to provide for certain additional procedural protections, in addition to the indemnification provided for in its amended and restated certificate of incorporation and bylaws, and intends to enter into indemnification agreements with any new directors and executive officers in the future.

    The Registrant has purchased and currently intends to maintain insurance on behalf of each and any person who is or was a director or officer of the Registrant against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.

    See also the undertakings set out in response to Item 9 herein.


    Item 8. Exhibits.

    The Registrant has filed the exhibits listed on the accompanying Exhibit Index of this Registration Statement.

    EXHIBIT INDEX

     

    Exhibit

    Number

           

    Incorporated by Reference

      

    Exhibit Description

      

    Form

      

    File No.

      

    Exhibit

      

    Filing Date

    4.1    Specimen common stock certificate of the Registrant    S-1/A    333-216574    4.1    April 3, 2017
    5.1*    Opinion of Wilson Sonsini Goodrich & Rosati, P.C.            
    10.1    2020 Inducement Equity Incentive Plan    S-8    333-244407    10.1    August 11, 2020
    10.2    Form of stock option agreements under the 2020 Inducement Equity Incentive Plan    S-8    333-244407    10.2    August 11, 2020
    23.1*    Consent of Independent Registered Accounting Firm (KPMG LLP)            
    23.2*    Consent of Wilson Sonsini Goodrich & Rosati, P.C. (included in Exhibit 5.1 hereto).            
    24.1*    Power of Attorney (included on the signature page hereto).            
    107*    Filing Fee Table            

     

    *

    Filed herewith.

    Item 9. Undertakings.

    A. The undersigned Registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

    provided, however, that paragraphs (A)(1)(i) and (A)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in this Registration Statement.

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.


    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    B. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    C. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Dallas, State of Texas, on September 30, 2025.

     

    FORTE BIOSCIENCES, INC.
    By:  

    /s/ Paul A. Wagner, Ph.D.

      Paul A. Wagner, Ph.D.
      Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Paul A. Wagner Ph.D. and Antony Riley, and each of them, as such individual’s true and lawful attorney in fact and agent with full power of substitution, for such individual in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8 (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney in fact, proxy and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney in fact, proxy and agent, or the individual’s substitute, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

     

    Signature

      

    Title

     

    Date

    /s/ Paul A. Wagner, Ph.D.

    Paul A. Wagner, Ph.D.

      

    Director and Chief Executive Officer

    (Principal Executive Officer)

      September 30, 2025

    /s/ Antony Riley

    Antony Riley

      

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

      September 30, 2025

    /s/ Scott Brun, M.D.

    Scott Brun, M.D.

       Director   September 30, 2025

    /s/ Stephen Doberstein, Ph.D.

    Stephen Doberstein, Ph.D.

       Director   September 30, 2025

    /s/ Barbara Finck, M.D.

    Barbara Finck, M.D.

       Director   September 30, 2025

    /s/ David Gryska

    David Gryska

       Director   September 30, 2025

    /s/ Shiv Kapoor

    Shiv Kapoor

       Director   September 30, 2025

    /s/ Steven Kornfeld

    Steven Kornfeld

       Director   September 30, 2025

    /s/ Rich Vincent

    Rich Vincent

       Director   September 30, 2025
    Get the next $FBRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FBRX

    DatePrice TargetRatingAnalyst
    8/18/2025$75.00Buy
    Guggenheim
    1/21/2025Buy
    TD Cowen
    4/8/2024$2.75Neutral → Buy
    Ladenburg Thalmann
    9/20/2021$4.00 → $3.50Sell → Buy
    Chardan Capital Markets
    9/20/2021$4.00 → $3.50Sell → Neutral
    Chardan Capital
    9/3/2021Buy → Hold
    Brookline Capital
    9/3/2021Buy → Neutral
    Ladenburg Thalmann
    9/3/2021$105.00 → $4.00Buy → Sell
    Chardan Capital Markets
    More analyst ratings

    $FBRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Riley Antony A bought $124,998 worth of shares (22,514 units at $5.55), increasing direct ownership by 273% to 30,776 units (SEC Form 4)

    4 - Forte Biosciences, Inc. (0001419041) (Issuer)

    11/22/24 5:45:42 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wagner Paul A. bought $7,525 worth of shares (10,000 units at $0.75), increasing direct ownership by 0.55% to 1,823,236 units (SEC Form 4)

    4 - Forte Biosciences, Inc. (0001419041) (Issuer)

    12/20/23 10:56:32 AM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wagner Paul A. bought $14,551 worth of shares (20,520 units at $0.71), increasing direct ownership by 1% to 1,813,236 units (SEC Form 4)

    4 - Forte Biosciences, Inc. (0001419041) (Issuer)

    12/15/23 6:29:33 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium

    Additional data continues to support highly differentiated profile for FB102 in celiac disease Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced additional details from the oral presentation "FB102 prevents histological damage and mitigates gluten challenge-induced symptoms in a celiac disease phase 1b study - Jason Tye-Din, Walter and Eliza Hall Institute; Royal Melbourne Hospital" at the Tampere Celiac Disease Symposium 2025 (Tampere, Finland) on Friday September 12, 2025, further supporting the significant differentiation of FB102 in celiac disease. Highlights of the

    9/15/25 9:00:00 AM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forte Biosciences, Inc. Announces Results and Provides Update

    Three clinical trial readouts for FB102 expected in 2026, including phase 2 in celiac disease and phase 1b in both vitiligo and alopecia areata Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its second quarter 2025 financial results and provided a business update. "I am deeply appreciative of the Forte team's incredible accomplishments in initiating 3 clinical trials for FB102 with data readouts shortly." said Forte Biosciences CEO Paul Wagner, PhD. "We have begun dosing subjects in the FB102 phase 2 celiac disease clinical trial and look forward to reporting to

    8/14/25 4:01:00 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forte Biosciences Announces Pricing of $75 Million Public Offering

    Forte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,630,450 shares of its common stock at a price to the public of $12.00 per share and, in lieu of common stock to certain investors who so chose, pre-funded warrants to purchase up to 619,606 shares of common stock at a price to the public of $11.999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.001 per share exercise price for each pre-funded warrant. In addition, Forte has granted the underwriters a 30-day option to purchase up to

    6/25/25 12:28:00 AM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBRX
    SEC Filings

    View All

    SEC Form S-8 filed by Forte Biosciences Inc.

    S-8 - Forte Biosciences, Inc. (0001419041) (Filer)

    9/30/25 4:05:45 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Forte Biosciences Inc.

    SCHEDULE 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

    9/5/25 9:38:51 AM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Forte Biosciences Inc.

    SCHEDULE 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

    8/14/25 4:27:46 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Riley Antony A converted options into 375 shares and covered exercise/tax liability with 134 shares, increasing direct ownership by 0.77% to 31,599 units (SEC Form 4)

    4 - Forte Biosciences, Inc. (0001419041) (Issuer)

    7/3/25 4:22:07 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Wagner Paul A. converted options into 1,250 shares and covered exercise/tax liability with 98 shares, increasing direct ownership by 1% to 80,940 units (SEC Form 4)

    4 - Forte Biosciences, Inc. (0001419041) (Issuer)

    7/3/25 4:20:51 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF FINANCIAL OFFICER Riley Antony A converted options into 375 shares and covered exercise/tax liability with 154 shares, increasing direct ownership by 0.71% to 31,218 units (SEC Form 4)

    4 - Forte Biosciences, Inc. (0001419041) (Issuer)

    4/2/25 5:03:05 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Forte Biosciences with a new price target

    Guggenheim initiated coverage of Forte Biosciences with a rating of Buy and set a new price target of $75.00

    8/18/25 8:56:30 AM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Forte Biosciences

    TD Cowen initiated coverage of Forte Biosciences with a rating of Buy

    1/21/25 7:45:55 AM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forte Biosciences upgraded by Ladenburg Thalmann with a new price target

    Ladenburg Thalmann upgraded Forte Biosciences from Neutral to Buy and set a new price target of $2.75

    4/8/24 7:21:57 AM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBRX
    Leadership Updates

    Live Leadership Updates

    View All

    Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors

    Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor appointed to Jasper Audit and Compensation Committees REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Scott Brun, M.D., to Jasper's Board of Directors. Dr. Bru

    6/20/23 8:00:00 AM ET
    $CABA
    $FBRX
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update

     -FB-102 Continues to Advance Towards the Clinic and Holds Significant Market Potential Across a Variety of Indications- -Leadership Strengthened with the Appointment of Scott Brun, M.D. to the Board of Directors- -Ended third quarter 2022 with approximately $44.0 million in cash and cash equivalents- Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced third quarter 2022 results and provided a business update. "Forte is making excellent progress with its lead program FB-102, which is a direct result of the team's hard work and diligent efforts. FB-102 holds significant potential in a variety of indicatio

    11/14/22 4:01:00 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors

    -Forte Leadership is Significantly Strengthened with the Appointment of Dr. Scott Brun, M.D. to the Board of Directors Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), announced today that Dr. Scott Brun, M.D. has been appointed to the Forte Biosciences Board of Directors. Dr. Brun is currently a Venture Partner at Abingworth and in addition to his consulting practice, he is also a Senior Advisor for Horizon Therapeutics, and a Senior Medical Advisor at Launch Therapeutics. Dr. Brun previously served in numerous executive capacities at AbbVie, most recently as Head of AbbVie Ventures. In Dr. Brun's previous role as Head of Product Development at Abbvie, he led the global organi

    11/14/22 4:01:00 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBRX
    Financials

    Live finance-specific insights

    View All

    Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

    Phase 2 Celiac Disease Trial Initiating with Topline Readout Expected in 2026 Forte will be Hosting a Conference Call to Discuss the Results at 8:30 am ET Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101). The company will be hosting a conference call today at 8:30 am ET. Prof. Jason Tye-Din, Head of Celiac Research at the Walter and Eliza Hall Institute and principal investigator in the FB102-101 study will be participating in the call. Please connect to the call using the

    6/23/25 7:18:00 AM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance

    Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company, today announced that topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI). Positive trends were observed in key secondary endpoints including EASI-90 with 27.6% of subjects in the active arm achieving the EASI-90 endpoint compared to 20.5% in the control arm (p=0.3075) and in IGA success (2 point reduction and clear or almost clear) with 38.2% of active sub

    9/2/21 4:05:00 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7

    Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company, will review the second quarter results and, based on the projected timing of database lock and completion of statistical programming and analysis, expects to announce topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis on September 7, 2021. Conference Call and Webcast Information Forte management will host a conference call and webcast on Tuesday, September 7th at 8.00 AM Eastern Time. Participants may access the call by dialing 877-705-6003 (Domestic) or 201-493-6725 (International). The conference ID number is: 13722132. Participants may also

    8/16/21 4:05:00 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Forte Biosciences Inc.

    SC 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

    12/6/24 4:05:50 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Forte Biosciences Inc.

    SC 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

    11/14/24 4:31:51 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Forte Biosciences Inc.

    SC 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

    11/14/24 4:02:27 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care